German Stock Market: Whose Results Are Deceptive?
Numbers don't lie, but they don't always tell the whole truth either. The spring first-quarter reports have long been published by major German companies, and now, at the end of May, the initial dust on the markets has settled. As summer approaches and investors will soon begin shifting their focus to second-quarter expectations, now is the perfect time to look back and analyze what was actually hidden behind the spring numbers. We examine three well-known major German corporations whose headline profit numbers for the first quarter of 2026 are heavily distorted by extraordinary events.
Fresenius Medical Care's first-quarter headlines might have startled investors at first glance, as the company's reported operating profit fell by 13.6% year-over-year, landing at 286 million euros. Net profit also dropped by 21.9%, and revenue decreased by 5.5%. Following the growth trend of the previous quarter, this seemed like a sharp setback, briefly driving the stock price to a one-year low in early May.
In reality, however, this profit decline is planned and temporary, as the numbers include one-off costs from the FME25+ transformation program and major strategic IT investments. Excluding these extraordinary expenses, the company's underlying profit actually grew by 2.0%. For investors, this means that the company's core business is more stable than the initial numbers suggest, and the ongoing savings programs should instead support profitability in the long run.
The first-quarter numbers of the pharmaceutical and chemical conglomerate Bayer offered investors great relief, as the company's operating profit grew by 10.1% year-over-year, reaching 3,204 million euros. Even more striking was the 112.7% growth in net profit to 2,763 million euros. After the massive loss in the previous quarter, this seemed like a rapid turnaround for the better, injecting new optimism into the markets.
However, behind this beautiful growth lies partly a low base of comparison caused by extraordinary expenses in the previous quarter, as well as a very strong performance by the agricultural division, which masks the real problems in the pharmaceutical business. Although the sales of soybean and corn seeds drove profits up, the group's total revenue still fell by 2.4%, pressured by patent losses on older drugs. Investors must therefore understand that while the agricultural business is currently pulling the wagon successfully, the company's pharmaceutical side needs new solutions for long-term success.
At first glance, the first-quarter report of the chemical industry giant BASF showed a thoroughly decent result, as the company's operating profit grew by 5.3% year-over-year, amounting to 1,261 million euros. Net profit also showed a growth of 14.7%. In such a challenging economic environment, growing profits seems like a good achievement, which could indicate the company's strong market position and growing demand.
Upon closer inspection, however, it turns out that this profit growth is deceptive, as the company's actual sales revenue simultaneously plummeted by a whopping 8.5%, falling to 16.02 billion euros. The increase in profit came solely from the fact that extraordinary costs related to restructuring were significantly lower this year than last year. For an investor, this is a clear warning sign: profit was not grown by successful business operations and strong demand, but simply by lower one-off costs against a backdrop of declining sales.
Conclusion
The first-quarter results of major German companies are an excellent reminder that numbers always need context. In the case of Fresenius Medical Care, necessary future investments made today's picture artificially ugly, while for BASF, lower extraordinary costs masked an actual decline in sales. The example of Bayer, however, teaches that the strength of one business line and base effects can hide the weaknesses of other departments. A smart investor never buys or sells based solely on the headline of the first press release, but always reads the fine print to understand the true health of the company.
RYTM content is for informational purposes only, not financial advice or recommendations. You are solely responsible for your investment decisions. Always consult a professional.